Recent studies have highlighted the critical dependence of AML cells with the NUP98 rearrangement on the interaction between Menin and MLL1, suggesting that pharmacological inhibition of this interaction may be a promising therapeutic strategy. The gene discussed is KMT2A; the disease is acute myeloid leukemia.